Do mild elevations in ALT and GGT indicate MASLD and reflect hepatic insulin resistance and oxidative stress?

Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by a complex interplay of metabolic disturbances and hepatocyte injury. Mild elevations in alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) are hallmark clinical features of this condition, often serving as the initial biochemical "red flags" that prompt further diagnostic investigation.

Clinical evidence and biomarkers

Serum elevations of ALT and GGT are highly prevalent in patients with MASLD and are recognized by major clinical guidelines (EASL-EASD-EASO) as primary triggers for screening in individuals with cardiometabolic risk factors.

• ALT Correlation: ALT levels exhibit a dose-dependent relationship with MASLD severity. Research indicates that individuals with ALT ≥80 U/L have a significantly higher prevalence of significant fibrosis (38.9%) compared to those with lower levels.
• GGT and Risk: GGT is widely used as a marker of MASLD presence and correlates positively with cardiometabolic risk markers, although it is considered less specific for liver injury than ALT.
• The "Normal" Range Caveat: It is critical to note that nearly 33% of patients with advanced fibrosis may maintain "normal" enzyme levels (31–54 U/L). Consequently, these enzymes are increasingly integrated into non-invasive test (NIT) algorithms rather than being used as standalone diagnostic markers.

Mechanistic explanations

The tracking of these enzymes with metabolic dysfunction is rooted in specific cellular and biochemical pathways:

• Hepatic Insulin Resistance: ALT is a robust marker of hepatic insulin resistance. Its elevation correlates with indices like HOMA-IR and fasting insulin. Mechanistically, lipotoxicity and mitochondrial dysfunction from excess free fatty acids impair insulin signaling. This leads to hepatocyte injury and the subsequent release of ALT into the bloodstream.
• Oxidative Stress and GGT: GGT is a sensitive indicator of oxidative stress due to its role in glutathione (GSH) metabolism. As a cell-surface enzyme, GGT degrades extracellular GSH to provide cysteine for intracellular GSH resynthesis. Under oxidative burden, GGT expression increases via redox-sensitive pathways to replenish antioxidant stores. This biochemical shift correlates with oxidative stress markers such as malondialdehyde (MDA) and nitrotyrosine.

Bottom line

Mild elevations in ALT and GGT are common in MASLD and directly reflect underlying pathophysiology: ALT serves as a proxy for hepatocyte injury driven by insulin resistance and lipotoxicity, while GGT signals the adaptive response to hepatic oxidative stress. However, because advanced disease can exist even with enzyme levels in the standard reference range, these markers should be interpreted within the broader context of metabolic risk and non-invasive fibrosis assessments.